Standard Chem. & Pharm. Co., Ltd.   Report issue

For profit Phase 1 Phase 4
Founded: Taipei Taiwan (1967)
Status: No NME R&D (1967)

Organization Overview

First Clinical Trial
2014
NCT02151357
First Marketed Drug
2019
riluzole (rilutek)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

STANDARD CHEM AND PHARM CO LTD | STANDARD CHEM PHARM | Standard Chem. & Pharm. Co., Ltd.

Active Ingredients

Marketed Drugs (2)

fingolimod (gilenya) (2021)

riluzole (rilutek) (2019)

Drugs in Phase 4 Trials (1)

lurasidone (latuda) (1 trial)

Drugs in Phase 1 Trials (1)

dcbci0901 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Schizophrenia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2